相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
C. Cremolini et al.
ANNALS OF ONCOLOGY (2021)
The Role of Maintenance Strategies in Metastatic Colorectal Cancer A Systematic Review and Network Meta-analysis of Randomized Clinical Trials
Mohamad Bassam Sonbol et al.
JAMA ONCOLOGY (2020)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Filippo Pietrantonio et al.
JAMA ONCOLOGY (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
Hans-Joachim Schmoll et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Novel Precision Medicine Trial Designs Umbrellas and Baskets
Howard (Jack) West
JAMA ONCOLOGY (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
Alexander Stein et al.
CLINICAL COLORECTAL CANCER (2016)
Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials
Emiliano Tamburini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Susanna Hegewisch-Becker et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
A. Johnsson et al.
ANNALS OF ONCOLOGY (2013)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
